中华生物医学工程杂志
中華生物醫學工程雜誌
중화생물의학공정잡지
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
2012年
4期
292-295
,共4页
阮月芹%韩晓通%王敏%李卫%韩兆东
阮月芹%韓曉通%王敏%李衛%韓兆東
원월근%한효통%왕민%리위%한조동
杀伤细胞,淋巴因子激活%肿瘤%T淋巴细胞%杀伤细胞
殺傷細胞,淋巴因子激活%腫瘤%T淋巴細胞%殺傷細胞
살상세포,림파인자격활%종류%T림파세포%살상세포
Killer cells,lymphokine-activated%Neoplasms%T-lymphocytes%Killer cells
目的 探讨链式激活和诱导的免疫杀伤细胞(CAPRI细胞)治疗对肿瘤患者T淋巴细胞免疫功能的影响.方法 接受CAPRI细胞治疗的滨州医学院附属医院肿瘤内科收治的50例恶性肿瘤患者为研究对象(肿瘤组),同时选择体检健康者30例为对照组,用流式细胞术检测所有患者治疗前后外周血T淋巴细胞CD3+及CD4+、CD8+的百分率,计算CD4+/CD8+比值并进行比较.结果 肿瘤患者治疗前外周血CD3+、CD4+、CD8+、CD4+/CD8+[ (56.40±7.14)％、(30.69±8.01)％、(29.10±7.13)％、1.05 ±0.28]与健康对照组[(66.78±6.05)％、(41.35±5.71)％、(26.08±5.36)％、1.59±0.31]及治疗后13 d[ (59.35±6.31)％、(34.95±7.21)％、(27.95±6.03)％、1.25±0.22]和治疗后25d[(62.36±6.41)％、(37.03±7.62)％、( 25.04±4.53)％、1.46±0.48]比较,CD3+、CD4+、CD4+/CD8+均明显降低、CD8+均明显升高(均P＜0.05);治疗后25d与治疗后13d比较,CD3+、CD4+、CD4+/CD8+均明显升高、CD8+均明显降低(均P＜0.05).结论 CAPRI细胞治疗肿瘤,能够纠正CD3+、CD4+、CD8+、CD4+/CD8+失衡状态,能够调节机体T淋巴细胞的免疫功能.
目的 探討鏈式激活和誘導的免疫殺傷細胞(CAPRI細胞)治療對腫瘤患者T淋巴細胞免疫功能的影響.方法 接受CAPRI細胞治療的濱州醫學院附屬醫院腫瘤內科收治的50例噁性腫瘤患者為研究對象(腫瘤組),同時選擇體檢健康者30例為對照組,用流式細胞術檢測所有患者治療前後外週血T淋巴細胞CD3+及CD4+、CD8+的百分率,計算CD4+/CD8+比值併進行比較.結果 腫瘤患者治療前外週血CD3+、CD4+、CD8+、CD4+/CD8+[ (56.40±7.14)％、(30.69±8.01)％、(29.10±7.13)％、1.05 ±0.28]與健康對照組[(66.78±6.05)％、(41.35±5.71)％、(26.08±5.36)％、1.59±0.31]及治療後13 d[ (59.35±6.31)％、(34.95±7.21)％、(27.95±6.03)％、1.25±0.22]和治療後25d[(62.36±6.41)％、(37.03±7.62)％、( 25.04±4.53)％、1.46±0.48]比較,CD3+、CD4+、CD4+/CD8+均明顯降低、CD8+均明顯升高(均P＜0.05);治療後25d與治療後13d比較,CD3+、CD4+、CD4+/CD8+均明顯升高、CD8+均明顯降低(均P＜0.05).結論 CAPRI細胞治療腫瘤,能夠糾正CD3+、CD4+、CD8+、CD4+/CD8+失衡狀態,能夠調節機體T淋巴細胞的免疫功能.
목적 탐토련식격활화유도적면역살상세포(CAPRI세포)치료대종류환자T림파세포면역공능적영향.방법 접수CAPRI세포치료적빈주의학원부속의원종류내과수치적50례악성종류환자위연구대상(종류조),동시선택체검건강자30례위대조조,용류식세포술검측소유환자치료전후외주혈T림파세포CD3+급CD4+、CD8+적백분솔,계산CD4+/CD8+비치병진행비교.결과 종류환자치료전외주혈CD3+、CD4+、CD8+、CD4+/CD8+[ (56.40±7.14)％、(30.69±8.01)％、(29.10±7.13)％、1.05 ±0.28]여건강대조조[(66.78±6.05)％、(41.35±5.71)％、(26.08±5.36)％、1.59±0.31]급치료후13 d[ (59.35±6.31)％、(34.95±7.21)％、(27.95±6.03)％、1.25±0.22]화치료후25d[(62.36±6.41)％、(37.03±7.62)％、( 25.04±4.53)％、1.46±0.48]비교,CD3+、CD4+、CD4+/CD8+균명현강저、CD8+균명현승고(균P＜0.05);치료후25d여치료후13d비교,CD3+、CD4+、CD4+/CD8+균명현승고、CD8+균명현강저(균P＜0.05).결론 CAPRI세포치료종류,능구규정CD3+、CD4+、CD8+、CD4+/CD8+실형상태,능구조절궤체T림파세포적면역공능.
Objective To explore the impact of cascade primed immune(CAPRI) cell therapy on the immune function of T lymphocytes in patients with malignant tumors.Methods A total of 50 cases of malignant tumors (tumor group) received CAPRI cell therapy in Department of Tumor in hospital and 30 healthy people as controls (control group) were enrolled in the study.The percentages of CD3+,CD4+ and CD8 + T lymphocytes were detected in peripheral blood by flow cytometry in all patients before and after treatment,then the ratio of CD4 +/CD8 + T lymphocytes was calculated and compared.Results Before treatment,the percentages of CD3+,CD4+,CD8+ and CD4+/CD8+ T lymphocytes in peripheral blood were (56.40±7.14)％,(30.69±8.01)％,(29.10±7.13)％ and 1.05±0.28 in tumor group,which were significantly decreased in CD3 +、CD4+、CD4 +/CD8 + but increased in CD8 + as compared with healthy control group [ (66.78±6.05,41.35±5.71,26.08±5.36)％,1.59±0.31],13 d after treatment[ (59.35±6.31,34.95±7.21,27.95±6.03)％,1.25±0.22] and 25 d after treatment[ (62.36±6.41,37.03±7.62,25.04±4.53)％,1.46± 0.48],all P＜0.05].After treatment,the percentages of CD3+,CD4+ and CD4+/CD8 + were significantly increased but CD8+ decreased in tumor group at 25 d as compared with 13 d (all P＜0.05).Conclusion CAPRI cell therapy for tumor can rectify the imbalance of CD3 +,CD4 +,CD8 + and CD4 +/CD8 + T lymphocytes,which can regulate the immune function of T lymphocytes.
